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Abstract: The foundations for cardiovascular disease in adults are laid in childhood and 
accelerated by the presence of comorbid conditions, such as obesity, diabetes, hypertension, and 
dyslipidemia. Early detection of vascular dysfunction is an important clinical objective to identify 
those at risk for subsequent cardiovascular morbidity and events, and to initiate behavioral and 
medical interventions to reduce risk. Typically, cardiovascular screening is recommended for 
young adults, especially in people with a family history of cardiovascular conditions. Children 
and adolescents were once considered to be at low risk, but with the growing health concerns 
related to sedentary lifestyle, poor diet and obesity, cardiovascular screening may be needed ear-
lier so that interventions to improve cardiovascular health can be initiated. This review describes 
comorbid conditions that increase cardiovascular risk in youth, namely obesity and diabetes, 
and describes noninvasive methods to objectively detect vascular disease and quantify vascular 
function and structure through measurements of endothelial function, arterial compliance, and 
intima-media thickness. Additionally, current strategies directed toward prevention of vascular 
disease in these populations, including exercise, dietary interventions and pharmacological 
therapy are described.
Keywords: endothelial function, arterial compliance, intimal medial thickness, inflammation, 
intervention
Introduction
The incidence of obesity in US children has increased almost threefold within the 
last three decades.1 With it has come insulin resistance,2 and a rarely before seen 
phenomenon, type 2 diabetes in childhood.1,3,4 Public health experts suggest that this 
early appearance of type 2 diabetes will result in a major societal health burden to 
the next generation, in large part because of anticipated debilitating cardiovascular 
comorbidities. Vascular disease in adulthood has been studied extensively with 
techniques used to assess both vascular function and anatomic pathology. Diabetes is 
a known risk factor for both micro and macrovascular disease, and the relationships 
among glycemia, lipid abnormalities, blood pressure control, vascular pathology, and 
cardiovascular events and mortality in diabetic adults are well described. Less is known 
about these interactions in children with diabetes, especially those with type 2 diabetes. 
Recently, preliminary results from the National Institutes of Health (NIH)-supported 
multicenter TODAY (Treatment Options for type 2 Diabetes in Adolescents and Youth) 
trial suggested that as many as 60% of children referred for new onset type 2 diabetes 
have some form of dyslipidemia, and 17% have hypertension (defined as a blood 
pressure greater than the 95th percentile for age, height, and sex).5,6 These associated Vascular Health and Risk Management 2009:5 974
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co-morbidities at or near diagnosis lend credibility to the 
suggestion that such children are at extremely high risk for 
developing premature vascular disease. Although vascular 
pathology in obese and diabetic children has been described, 
the time course of development of abnormalities in vascular 
function and anatomic pathology, and relationships among 
comorbidities are poorly understood.
In adults detectable abnormalities in vascular function 
typically precede the development of vascular anatomi-
cal pathology.7–10 Vascular dysfunction, including reduced 
endothelial function and arterial compliance and increased 
inflammatory markers, is detectable in obese and diabetic 
subjects prior the appearance of anatomical abnormalities.8–13 
This has led to the postulated sequence of events whereby 
early changes in vascular risk factors such as obesity, 
hyperlipidemia, hypertension, and impaired glycemia pro-
mote initial endothelial dysfunction and stiffness of small 
vessels. Inflammation and continued presence of these risk 
factors leads subsequently to atherosclerotic development 
with altered vascular structure and increased stiffness of the 
large vessels.10
Although children and young adults with familial 
hyperlipidemia and family history of type 2 diabetes are 
known to be at increased risk for early development of vas-
cular pathology,14–17 less is known about the independent risk 
factors of obesity and diabetes, and the role of inflammation in 
the process of vascular pathology development in childhood. 
Since children rarely develop major cardiovascular complica-
tions during childhood, and since type 2 diabetes in childhood 
is a relatively recent phenomenon, it is not surprising that 
reports defining pathological vascular function in childhood 
type 2 diabetes are limited. Components of the metabolic syn-
drome with or without diabetes are associated with evidence 
of pathological arterial changes in adolescence measured as 
the area of fatty streaks and raised plaques in post-mortem 
studies.18 Obese children routinely have been shown to 
have many of the proinflammatory, proathrogenic changes 
associated with vascular disease in adults, including insulin 
resistance, hepatic steatosis, elevated total-, low-density 
lipoprotein-cholesterol (LDL-C), and oxidized LDL-C, 
elevated levels of vascular adhesion molecules, tumor necrosis 
factor-α (TNF-α), C-reactive protein, interleukin-6 (IL-6), 
and fibrinogen, while high-density lipoprotein-cholesterol 
(HDL-C) and adiponectin are reduced.19–28 These deleterious 
changes set the stage of early development of vascular dys-
function and atherosclerosis. Most concerning is the evidence 
that these risk factors are fairly stable in adolescents if body 
mass index (BMI) is unchanged29 and track from adolescence 
into adulthood.30 Further, risk factors in adolescence predict 
preathersclerotic changes such as increased carotid intima-
media thickness (IMT) in adulthood.7,11,31,32 Thus, while overt 
atherosclerosis may not be evident in most obese or diabetic 
children, the predisposition to its development may be under-
way well before adulthood.
This review summarizes results of commonly used 
noninvasive techniques for assessing vascular health in chil-
dren, with recent data for normal patterns of development 
and aging. In addition this review summarizes evidence that 
obesity and diabetes in childhood are associated with vascular 
pathology, including speculation regarding the sequence of 
events leading to overt cardiovascular disease that occurs 
typically later in adulthood, and the likelihood of reversibility 
of pathology following interventions. Finally, we summarize 
the evidence for current lifestyle and pharmacological man-
agement effects on vascular health in children with obesity 
and type 2 diabetes.
Methodological approaches  
to assessing vascular function  
and structure
endothelial function
Methods of assessment
Endothelial function is often measured in adults and 
children with the noninvasive method of flow-mediated 
dilation (FMD). The most common method of assessing 
FMD is to measure the change in brachial arterial diameter 
in response to brief (five minutes) of arterial occlusion.33–37 
Flow occlusion is performed with a blood pressure cuff and 
Doppler ultrasound is used to image the artery diameter dur-
ing and for up to five minutes after occlusion.37–42 Once the 
cuff is released the resumption of flow creates shear stress on 
the vascular wall, which stimulates nitric oxide production 
by the endothelial lining and in turn causes relaxation of 
vascular smooth muscle.38,40,43 The brachial artery typically 
dilates ∼6%–12% in healthy people.40–42,44 Following FMD 
measurement, the endothelial-independent vasodilatory 
response can be assessed by sublingual administration 
of gyceryl trinitrate (GTN, nitroglycerin), which relaxes 
the vascular smooth muscle to cause a further increase in 
vessel diameter.13,45 Jarvisalo and colleagues46 reported that 
FMD and GTN-mediated brachial dilation are positively 
correlated (r = 0.46) in children while another study showed 
that values from the two methods were similarly reduced 
in children with obesity or type 1 diabetes compared to 
nonobese children.19Vascular Health and Risk Management 2009:5 975
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Although ultrasound has been the standard approach to 
measure FMD and associated changes in blood flow, this 
technique requires skilled operators and expensive instrumen-
tation, and acquiring reproducible results can be challenging. 
For this reason, results may vary among research sites and 
application to clinical practice has been limited.33,47 Recently, 
alternative methods that are less operator-dependent have 
been developed. These techniques utilize the same physiologic 
principles, and quantify reactive hyperemia as a change in 
fingertip perfusion pressure measured by tonometry48–50 or 
temperature51,52 following brachial arterial occlusion. Both of 
these fingertip methods have been used to assess differences in 
clinical populations, including the Framingham Heart Study 
cohort53,54 as well as studies in children.49,50,55 Recent work 
showed that the results of both fingertip methods were posi-
tively associated (r = ∼0.46) with the brachial FMD method 
in young healthy men.52 The finding that these correlation 
values were not higher might be expected since brachial 
artery FMD is considered a macrovascular index, whereas 
the fingertip tonometric and thermal measures might best 
be considered indices of small vessel (microvasculature) 
function. Interestingly, though, the digital tonometric results 
correlate positively with cutaneous reactive hyperemia 
(r = 0.55), another microvascular measure determined by laser 
Doppler monitoring of an adjacent finger, while the thermal 
response method has not been shown to correlate significantly 
with either tonometry or cutaneous hyperemia. These results 
suggest that different methodologies may assess separate or 
partially overlapping physiological components of vascular 
function and that use of multiple approaches could be poten-
tially useful to obtain complimentary information.52
Age-related and developmental changes
Several studies have demonstrated that endothelial function, 
measured by FMD, declines with age in adults without car-
diovascular disease.56–59 The decline in older adults has been 
reported to be evident in both arm and leg arteries56,59 and 
inversely related to the concentration of LDL-C in seden-
tary older people.58 Although FMD mesurements have been 
extensively performed on children to assess the effects of 
various conditions, there are relatively few data on normal 
developmental patterns of endothelial function. In a study 
of 105 children aged 9–16 years it was shown that the time 
course and peak FMD measured after occlusion were inversely 
associated with arterial diameter and total cholesterol con-
centration, but not age.60 Arterial diameter increases during 
childhood, indicating the possibility that changes in FMD 
may be more closely linked to growth and development than 
to age per se. A recent examination of determinants of FMD 
values in children and adults57 showed that FMD, measured as 
the percent change in brachial arterial diameter, was highest 
in children (aged 10 years, 10.7% FMD) and declined with 
increasing age in young adults (aged 27 years, 7.5%) and 
middle-aged/older adults (aged 58 years, 6.0%). Children had 
smaller arteries and higher shear stress after occlusion than 
adults. Adjusting FMD for shear stress eliminated the differ-
ence in FMD between children and young adults, while the 
oldest group remained significantly lower than both younger 
groups. Nevertheless, shear stress only accounted for ∼15% 
of the variation in FMD and an association with shear stress 
was not seen in children as in adults.57 These findings suggest 
that at least some components of endothelial function may 
be regulated through different mechanisms in children and 
adults and require further evaluation.
effects of obesity, diabetes, and other comorbidities
Numerous reports have described impairments in endothelial 
function by up to 50% in obese children and adolescents 
compared to normal weight peers, similar to findings in obese 
adults.13,19,20,22,40,41,44,61–65 Both endothelial-dependent FMD 
and endothelial-independent (response to GTN) vasodilata-
tion typically are related inversely to BMI in normal weight 
children60 and are reported to be lower in obese children 
in some,19,45,65 but not all66 studies. Several longitudinal 
prospective studies have shown that endothelial-dependant 
vasodilation is inversely associated with increased risk of 
cardiovascular events and death in older adults67,68 and in 
middle-aged adults without apparent heart disease risk.69 The 
endothelial-independent vasodilatory response appears to be 
less prognostic of disease, particularly in subclinical adult 
populations.69,70 Because the increase in childhood obesity 
and type 2 diabetes are relatively recent phenomena, and 
because cardiovascular disease develops over several years, 
morbidity and mortality data linking endothelial function to 
cardiovascular events in children are currently unavailable. 
However, it is likely that development of obesity early in 
life and sustained into adulthood would increase the risk of 
cardiovascular events earlier in life.
Beyond the effects of obesity, the presence of other 
metabolic risk factors has been inversely associated with 
impaired endothelial function in children, particularly 
increased concentrations of inflammatory markers, such 
as C-reactive protein, and total cholesterol or oxidized 
LDL-C.46,63,71,72 Micro- and macrovascular function have 
been shown to be reduced in adults with impaired glucose 
tolerance and type 2 diabetes compared to healthy controls73 Vascular Health and Risk Management 2009:5 976
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but similar data for children with type 2 diabetes are not 
yet available. Endothelial function is, however, reduced in 
children with type 1 diabetes, suggesting that glycemic con-
trol may be influential.19,49,72,74 Since type 2 diabetes is nearly 
always accompanied by obesity, endothelial function is likely 
to be reduced in the pediatric type 2 diabetes population, 
though it will be important to determine if diabetes imposes 
a further impairment beyond the effect of obesity. In adults 
with diabetes intensive glucose management is associated 
with a lower incidence of microvascular complications,76 and 
type 2 diabetic patients who experience large fluctuations 
in circulating glucose concentrations have even more acute 
impairment in endothelial function when compared to those 
with sustained high glucose concentration.75 A known risk 
factor for cardiovascular disease in adults, elevated blood 
pressure, was reported to be present in 17% of all obese 
children and adolescents with type 2 diabetes at screening 
for entry into the TODAY trial.5,6 Elevated blood pressure is 
encountered more commonly in obese compared to normal 
weight children, and systolic pressure is inversely associated 
with endothelial function.19 Perhaps even more importantly, 
elevated blood pressure during adolescence appears to be a 
predictor of endothelial dysfunction in adulthood. A longitu-
dinal prospective study of 2,109 young Finnish adults showed 
that systolic pressure measured in boys aged 12–18 years 
was negatively correlated with FMD scores measured at ages 
24–39 years. This relationship was not present for females, 
nor was there a significant relationship between blood pres-
sure at early ages (3–9 years) and the FMD value measured 
in early adulthood.77 Collectively, these findings suggest 
that endothelial function is affected adversely affected by 
the presence of multiple vascular risk factors. However, 
Mimoun and colleagues78 measured FMD and nitroglyceride-
stimulated brachial artery dilation in 161 obese children and 
reported that a subset of children who met current definitions 
for metabolic syndrome had endothelial function measures 
that were no different from those children without metabolic 
syndrome. Notably, this study did not report how many of 
the obese participants had elevated values for one or more 
components of metabolic syndrome and a normal weight 
reference group was not included.
Arterial compliance
Arterial compliance is the amount of arterial expansion and 
recoil that occurs with cardiac pulsation and relaxation, 
and is linked to both structural and functional properties of 
the artery.79 There are several noninvasive methods avail-
able to measure arterial compliance, including diastolic 
pulse contour analysis (PCA), pulse wave velocity (PWV), 
and high-resolution ultrasound.
Methods of assessment
Diastolic PCA is a widely used method that provides indices 
of both large and small arterial compliance.80 Large artery 
compliance (capacitive compliance) and small artery compli-
ance (reflective compliance) are calculated through analysis 
of the decay in the diastolic blood pressure waveforms and 
reflected waveforms.81 An advantage of diastolic PCA is that 
it allows an assessment of small artery compliance, which 
provides an index of the microcirculation and endothelial 
function; this is in contrast to the tonometric determination 
of carotid or femoral arterial pulse wave velocity that assesses 
only central and large artery compliance.82 Other cardiovascu-
lar parameters obtained during waveform collection include 
blood pressure, pulse rate, systemic vascular resistance, and 
total vascular impedance. Diastolic PCA measurements of 
arterial compliance are valid and reliable in adults.83
Arterial compliance is also assessed by measuring 
PWV using pressure tonometers placed at two arterial sites 
(applanation tonometry, eg, typically radial and carotid), and 
electrocardiogram-recorded timing of the transit of a pulse 
pressure wave. Other clinically significant measures that can 
be obtained from applanation tonometry include the augmen-
tation index, as well as pulse pressures obtained from brachial, 
aortic, and carotid sites.84 Augmentation index and pulse pres-
sure both correlate highly with cardiovascular mortality and 
events.85,86 Ultrasound approaches are used to assess arterial 
compliance as the change in lumen diameter from diastolic 
to systolic phases, typically at the carotid artery.87 All of the 
methods used to measure compliance may vary with the 
site of measurement (central versus peripheral) and must be 
adjusted for pulse pressure. Care must be taken to standard-
ize measurements to control for several factors that affect the 
measurements including time of day, smoking, intake of food, 
caffeine or other stimulants, prior exercise, room temperature, 
menstrual cycle phase, and mental stress.
Age-related and developmental changes
In healthy adults, carotid stiffness increases with age, and 
is positively related to blood pressure and BMI but has 
not been reported to differ with sex.87 Likewise, systemic 
arterial compliance decreases in adults from the ages of 
21–96 years.10,88,89 A study by Collins and colleagues,90 using 
the brachial-ankle PWV method suggested that the decline 
in peripheral large arterial compliance begins in adoles-
cence. As shown in Figure 1, however, Gardner and Parker,91 Vascular Health and Risk Management 2009:5 977
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recently reported that both large and small arterial elasticity, 
assesed using radial artery PCA, increase from the age of 
seven years through adolescence in healthy people, peak-
ing in the early- to mid-20’s. That study also showed, in 
agreement with McVeigh,88 that the decline in small artery 
elasticity during adulthood is of a greater relative magnitude 
than the change in large artery elasticity. At least part of the 
age-related decline in adults may be due to the cummulative 
effect of reduced physical activity as it has been shown that 
arterial compliance is maintained at youthful levels in older 
people who exercise regularly.89,92,93 The differences in arterial 
compliance changes during adolescence reported by Gardner 
and Parker91 and Collins and colleagues90 may be attributable 
to variations in the measurment techniques employed, study 
population, or other factors such as lifestyle. This variation 
hightlights the need to further define developmental changes 
in arterial compliance with complimentary approaches.
effects of obesity, diabetes, and other comorbidities
As in adulthood, central arterial compliance measured 
most commonly by PWV , is lower in youth who are obese. 
Compliance and elasticity of the carotid artery was shown 
to be impaired in obese children and young adults in some 
studies,62,94 although a recent report on a small number of 
children did not confirm this finding.66 Another recent study 
of more than 500 Australian school children, average age 
10 years, showed that carotid-femoral PWV was positively 
correlated with BMI and percentage body fat,95 supporting 
the idea that adiposity results in increased stiffness of large 
arteries even at a young age. In contrast, obese adolescent 
girls (mean age 14 years) were shown to have lower PWV 
and higher arterial diameters compared to lean adolescent 
girls, despite increased radial intimal thickness.96 The authors 
who reported this unexpected result proposed that hyperinsu-
linemia associated with obesity and relative insulin resistance 
might stimulate chronic vasorelaxation and higher vascular 
compliance. Additionally, we suggest that the higher arterial 
compliance in childhood obesity might indicate developmen-
tal change associated with maturation. This hypothesis is in 
accord with our own data using PCA, which shows increas-
ing arterial small and large vessel compliance in childhood 
(Figure 1). Since obese children are relatively taller and 
more sexually mature compared with their normal weight 
peers, they may have higher arterial compliance throughout 
childhood than normal weight children before reaching their 
peak arterial compliance as young adults. Nevertheless, it 
is clear that more widespread application of these newer 
assessment methods first will require establishment of age 
and developmental stage-related norms.
Most of the data available regarding the effect of 
diabetes on arterial compliance have been reported only in 
adults. Components of the metabolic syndrome are strongly 
predictive of reductions in both small and large arterial 
compliance in adults, with obesity and hypertension having 
the greatest impact.97–99 Adults with either type 1 or type 
2 diabetes have reduced arterial compliance compared to 
nondiabetic subjects.100,101 Further, for those with type 2 
diabetes, increased arterial stiffness, assessed by aortic 
PWV , was positively associated with peripheral neuropathy 
(odds ratio: 1.8) and retinopathy (odds ratio: 3.8), even after 
Figure 1 Changes in large and small arterial elasticity with age in children and adults. 
Measurements acquired using radial artery tonometry and diastolic pulsewave contour 
analysis in healthy people across the age span.  Adapted with permission from Gardner 
Aw, Parker De.   Association between arterial compliance and age in participants 9 to 
77 years old. Angiology. 2009; Jul 27. [epub ahead of print].
Abbreviations: LAei, large arterial elastic index; SAei, small arterial elastic index.
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controlling for several potentially confounding metabolic 
variables.101 A familial influence of type 2 diabetes has been 
shown to impact arterial compliance in early adulthood. At 
least two studies have shown that either carotid-radial or 
carotid-femoral PWV is reduced in normoglycemic, nor-
motensive young adults who are offspring of parents with 
type 2 diabetes when compared to control groups without 
diabetes family history.15,17 The small amount of data avail-
able to date indicate that carotid compliance and elasticity 
are reduced in adolescents and young adults with type 2 dia-
betes, compared to those measurements in lean nondiabetic 
peers, but are not different from obese participants without 
diabetes.94 This shows that arterial compliance is impaired in 
young type 2 diabetic subjects but suggests that diabetes in 
youth may pose an additional burden on arterial compliance 
beyond that of obesity. This finding needs to be confirmed 
and extended, including additional central and peripheral 
measures of compliance.
Hypertension also correlates closely with arterial com-
pliance. In adults with hypertension, arterial compliance is 
lower than that of matched controls.97,102,103 In young adults 
(average age 23 years) large and small arterial compliance, 
assessed with radial artery tonometry, were inversely related 
to blood pressure over a wide range of blood pressure 
values.104 Similar data in children are limited in this area. In a 
study of children considered to be at increased cardiovascular 
risk because of the presence of elevated blood pressure and 
total cholesterol, carotid elasticity was found to be reduced 
compared to an age-matched control group.105 The at-risk 
group also had evidence of higher body fat assessed by 
skinfolds so it remains to be demonstrated which of these 
variables (blood pressure, lipids, obesity), all of which tend 
to cluster clinically, contributed to the differences in arterial 
compliance observed. More recently it was shown that hyper-
tensive children have reduced carotid elasticity, although 
carotid compliance was higher.106 Together the existing data 
demonstrate that arterial stiffness is increased in adults with 
obesity, diabetes and hypertension. The limited data available 
in children tend to support the same conclusion.
intima-media thickness (iMT)
Methods of assessment
Measurement of IMT is performed using high-resolution 
ultrasonography, most often at the carotid artery, though 
peripheral sites have also been examined.106–109 A skilled 
operator is required and probe placement must be optimized 
for each patient to locate stable images of regions of interest. 
Images typically are collected from the leading edge of 
the lumen-intima interface on the far wall of the vessel. 
Visualization of IMT can be challenging because the vessel 
thickness is small (reported average values in normal and 
obese children and adults range from 0.34–0.80 mm), but 
differences within comparison groups or in longitudinal 
studies may only be 10%–15% (30–100 µm). Differences 
in technique and measurement site can add to the variability 
both within and between research groups and test–retest 
variation within the same participants only a month apart, 
even when conducted by an experienced group, can be low.110 
However, use of automated contour identification methods 
for the analyses can reduce subjective image quantification, 
and is reported to reduce the variability while increasing the 
number of measurement points analyzed.111,112 There may still 
be some inherent biological variability related to the choice 
of measurement location. Urbina and colleagues94 recently 
reported that IMT in the internal carotid was significantly 
higher in a large group of obese children and young adults 
(mean age 17.8 years, range 10–24) compared to age- and 
sex-matched nonobese participants, but did not differ with 
obesity when measured in the common carotid or at the 
carotid bulb locations. Despite some of these challenges, col-
lective evidence has shown that IMT increases with age and 
obesity but is responsive to dietary or exercise interventions 
lasting at least six months, as subsequently described.
Age-related and developmental changes
Artery diameter increases with age in children as part of 
normal development, particularly in the lumen.108,109 Whether 
IMT changes with age is less clear. Some studies show an 
increase in carotid IMT with age in children108,113 while oth-
ers show little or no change.109,110,114 This is likely due to the 
very small changes that occur and the technical challenges 
of precise, reliable measurements. Femoral IMT increases 
with age in children but the changes are also small.108,109 
Additionally, vessel wall density, particularly in the aorta, has 
been demonstrated to increase during childhood.115 During 
adulthood vessel size (common carotid) remains stable but 
the IMT increases, particularly in the presence of cardiovas-
cular risk factors, including obesity.11,57
effects of obesity, diabetes, and other comorbidities
In adults the presence of increased carotid IMT is associ-
ated with an increased risk of cardiovascular events.107,116,117 
Several studies have reported increased carotid or periph-
eral IMT in obese prepubertal children and adolescents 
aged 11–14 years old.21–23,62,66,94,96 In those studies, elevated 
IMT was associated with higher blood pressure, insulin Vascular Health and Risk Management 2009:5 979
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resistance or inflammatory markers. In the study by Meyer 
and colleagues22 performed in 14-year-old boys and girls, 
elevated IMT was also associated with lower brachial FMD. 
In contrast, another study reported no effect of obesity on 
carotid IMT in prepubertal children aged 6–11 years, despite 
the presence of elevated blood pressure and lower brachial 
FMD in the obese group.13 The lack of difference in IMT in 
that study may be due to the relatively younger developmen-
tal age of the participants compared to other investigations. 
This reflects the challenge of identifying small differences 
in vascular wall thickness among groups. The finding that a 
reduction in FMD was evident while a change in IMT was not 
detected supports the hypothesis that functional changes are 
likely to precede anatomic changes in vascular health.
One of the best recognized risk factor correlates with IMT 
in children is blood pressure. In a multivariate analysis of 
96 obese boys and girls aged 9–13 years, predictors of carotid 
IMT included systolic blood pressure, C-reactive protein, BMI, 
and fasting glucose, with systolic blood pressure contributing 
the most (15%) to the variance in IMT.23 Further, increased 
IMT is often found in children with hypertension.106,118,119 The 
study by Lande and colleages119 conducted in 10–18-year-old 
children confirmed that daytime systolic blood pressure, mea-
sured with ambulatory monitoring, was positively correlated 
(r = 0.57) with carotid IMT. Thus, hypertension appears to be 
key to promoting the vascular remodeling that is commonly 
seen in obese adolescents.
Metabolic syndrome and diabetes also appear to 
contribute to increased IMT. In a study of young adults 
(mean age ∼32 years) without diabetes carotid IMT 
increased progressively with the number of metabolic 
syndrome components present.120 Consistent with other 
studies, elevated blood pressure, either systolic 130 or 
diastolic 85 mm Hg, was the strongest single predictor 
of IMT, but low HDL-cholesterol (40 mg/dL) was also 
closely related. Fasting glucose 110 mg/dL, triglycerides 
150 mg/dL and waist circumference (102 cm for men 
or 88 cm for women) contributed progressively less to the 
variation in IMT.120 Likewise, in overweight Latino children 
(mean age 11 years) who were followed over three years, 
consistent presence of metabolic syndrome at annual visits 
was associated with higher carotid IMT compared to those 
children without metabolic syndrome.121 In comparison, in a 
study of 161 obese children, IMT, FMD, and arterial compli-
ance were not significantly different in the subset of children 
with metabolic syndrome compared to those without.78 
However, individual components of the metabolic syndrome 
and their potential relationships to IMT were not analyzed 
in that study. Nevertheless, there does appear to be some 
relationship between glycemic control and vascular struc-
tural pathology since carotid IMT is reported higher in both 
children with type 1 diabetes and young adults with type 2 
diabetes. In children with type 1 diabetes carotid IMT values 
were 12% higher than age-matched peers with similar BMI, 
lipids and blood pressure.72 The effect of type 2 diabetes on 
IMT in early life has only recently been reported. Urbina and 
colleages94 showed that carotid IMT was higher in children 
and young adults (age range 10–24 years) with type 2 diabetes 
compared to lean or obese peers when measured at the com-
mon carotid or carotid bulb with a trend to be higher at the 
internal carotid site as well. As might be expected for a group 
of children who developed type 2 diabetes at such a young 
age, the diabetic group in that study had several confound-
ing risk factors compared to the lean or obese nondiabetic 
groups, including abnormalities in blood pressure, total cho-
lesterol, triglycerides, glucose and insulin, all of which might 
have contributed so these differences may contribute to the 
variation in IMT results observed. Nevertheless, modeling 
analysis showed that the predicted increase in IMT from the 
age of 10–24 years was negligible in lean participants, but 
accelerated by both obesity and type 2 diabetes. Although 
the study was cross-sectional, these findings support the 
likelihood that childhood obesity and early onset diabetes 
accelerate the appearance of atherosclerosis in adulthood.
Further support that childhood obesity and presence of 
risk factors negatively affect vascular health in adulthood has 
been provided by prospective studies that followed children 
for 3 decades. The Muscatine Study (Muscatine, IO), 
which began data collection on 14,000 school children 
in the 1970s showed that risk factors measured at the 
age of 8–11 years were predictive of IMT in a subset of 
750 participants when those men and women reached the 
age of 33–42 years.32 Adult IMT was positively associated 
with childhood LDL-C concentration in both males and 
females, tryglyceride concentration and BMI in females, 
and HDL-C and diastolic blood pressure in males. A similar 
investigation over the same time period, the Bogalusa Heart 
Study (Bogalusa, LA), confirmed that elevated LDL-C and 
BMI in childhood were positive predictors of carotid IMT 
in adulthood.11 Further analysis of those data showed that 
both childhood and adult BMI explained variation in the 
adult IMT value.110 After controlling for several covarites the 
effect of childhood obesity on adult IMT was smaller than 
the effect of adult obesity, but childhood obesity remained 
a statisitically significant predictor. The unique finding was 
that neither obese children who were no longer obese adults, Vascular Health and Risk Management 2009:5 980
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nor lean children who did not become obese until adulthood, 
had elevated IMT when measured in their 30’s.110 Perhaps the 
key message to emerge from these studies is that long term 
obesity, present from childhood into adulthood, is most likely 
to be associated with elevated IMT. A similar longitudinal 
study conducted in Finland has reached many of the same 
conclusions, and has recently reported that childhood levels 
of serum apolipoproteins B and A-I, measured at the age of 
8–10 years, were significantly correlated with carotid IMT 
when measured in young adulthood (24–39 years).7 Fur-
thermore, the Finnish group found that the apo B/apo A-I 
ratio was a better predictor of adult IMT than either LDL-C 
or LDL/HDL ratio. Collectively, these studies indicate that 
obesity status tracks from childhood into adulthood, and 
emphasize the need to prevent obesity early in life.
Prevention and clinical management 
of  vascular dysfunction
Management of risk factors with or without diabetes begins 
with lifestyle prescription and education. Incorporation of 
intensive diet and exercise instruction can effectively modify 
components of the metabolic syndrome for a year or more,122 
and improve endothelial function.61 There is a tendency to 
prescribe dietary change with or without the assistance of 
a dietitian in the clinical setting, whereas exercise training 
is rarely prescribed, but should be strongly encouraged for 
the benefits outlined below. Exercise can improve insulin 
sensitivity, glycemic control, endothelial vascular function, 
and blood pressure.123 It has been recommended that all 
children with diabetes diagnosed at or after puberty have a 
fasting lipid profile performed soon after diagnosis when the 
blood glucose has been brought under control.122 If lipids are 
abnormal, annual monitoring is recommended. Initial therapy 
should consist of optimizing glucose control with exercise 
and diet, prescribing an American Heart Association step 2 
diet with the main goal of lowering the saturated fat in the 
diet. We believe that the goal of lipid control in children and 
adolescents with type 2 diabetes should be to reduce LDL-C 
to less than 100 mg/dL (2.6 mmol/L), a goal which can 
often be difficult to attain with optimal glucose control and 
diet alone. When lifestyle interventions fail, pharmacological 
treatments should be considered as outlined below.
Family history, reflecting combined effects of genetics 
and environmental influence, are strongly associated with 
vascular health and attempts at treatment. For example, 
families with type 2 diabetes history are more likely to 
have increased coronary artery calcification.14 In nor-
moglycemic and normotensive adult offspring of type 2 
diabetic parents, endothelial function was lower and arterial 
stiffness higher, independent of metabolic syndrome in one 
study15 while another study reported normal carotid IMT 
but decreased carotid compliance in diabetic offspring.16 
Likewise, young adults with diabetic parents were shown 
to have lower peripheral arterial compliance (higher PWV) 
than age-matched controls without diabetes history.17 
Thus, all treatment goals and progress should be evaluated 
in light of familial influence.
exercise and diet
There is evidence that physical activity and diet exert strong 
effects on vascular measurements in children. A study of 
nearly 500 adolescents demonstrated a positive relation-
ship between FMD score and leisure time physical activity 
assessed by questionnaire in 13-year-old boys,124 although 
this relationship did not hold for girls. The authors suggested 
that the lower physical activity values reported for girls may 
account for the difference between sexes, but there may 
also be some variability introduced by assessing habitual 
activity by questionnaire. Using a more objective approach 
to assess energy expenditure with the doubly labeled water 
technique, Abbott and colleagues125 reported that free-living 
physical activity was positively related to FMD in a group 
of 47 boys and girls aged 5–10 years, even after accounting 
for effects of age and body fatness. Similarly, FMD was 
shown to be positively related to physical activity in chil-
dren (mean age ∼10 years) using physical activity monitors 
to measure body movement.126 In that study the amount of 
moderate-to-vigorous activity was most closely associated 
with FMD values, whereas the volume of low level activity, 
such as activities of daily living, was unrelated to endothelial 
function.
Several investigations have shown that moderate intensity 
exercise can improve endothelial function in adults, includ-
ing those with diabetes, hyperlipidemia, or cardiovascular 
disease.127 By comparison, cessation of physical activity in 
healthy adults during bed rest results in a rapid decline in the 
reactive hyperemic response within 3–5 days.128 The effect 
of exercise has been proposed to be potentially independent 
of changes in other risk factors. Green and colleagues127 
conducted exercise training programs with combined aerobic 
and resistive components for eight weeks in a diverse group of 
middle-aged clinical patients and healthy participants. They 
showed that forearm FMD improved after training despite no 
significant changes in lipids, blood pressure, fasting glycemia, 
or BMI and that the change in FMD was not associated with 
changes in these or other risk variables. These findings Vascular Health and Risk Management 2009:5 981
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suggest that exercise may mediate an independent effect on 
vascular function by repeated exposure to increased shear 
stress during physical activity and that concurrent improve-
ment in endothelial function and traditional risk factors in 
response to training may not be causally related.
Exercise training effects on vascular measures in chil-
dren typically match those in adults. Watts and colleagues129 
reported that obese children aged 14 years, had FMD values 
that were 50% lower at baseline compared to a group of nor-
mal weight peers. In response to an eight-week aerobic and 
resistance exercise program, FMD was increased to the point 
of being similar to normal weight control values despite no 
significant change in body weight and only a small reduction 
in abdominal fat. The improvement in FMD was fully lost in a 
subset of the group who were retested eight weeks after train-
ing was stopped. Likewise Meyer and colleagues63 reported 
that obese children (mean age 14 years), had FMD values 
that were 55% lower and carotid IMT values that were 28% 
higher than lean children of the same age. After completing a 
six-month aerobic exercise program consisting of swimming, 
walking, and sports games, FMD improved 80% and IMT 
declined 8%, though neither change was enough to normalize 
differences compared with lean control values. There also 
were improvements in BMI, body fatness, fasting insulin, 
triglycerides, LDL-C and C-reactive protein, although the 
children remained clinically obese. More recently, FMD 
improved in a group of overweight children (mean age 
10 years) after a 12-week program of aerobic dance train-
ing, despite no changes in several inflammatory markers.130 
Together, these findings illustrate that exercise can result in 
improvements in several risk factors and vascular measures 
associated with obesity without full correction of excess 
body weight, and that persistent exercise adherence may be 
required in order to maintain those benefits.
In contrast to exercise, dietary interventions focused on 
energy restriction have yielded equivocal effects on vascular 
function in overweight children. Kaufman and colleagues131 
reported that 11-year-old children who completed a five-
month weight loss program (mean reduction of 2.4 kg body 
weight) showed improvements in brachial FMD (15%) and 
GTN-mediated dilation (20%). These changes occurred 
despite no significant changes in fasting glucose, lipids, 
or systolic blood pressure, although diastolic pressure and 
C-reactive protein concentration declined. On the other hand 
a study by Ribeiro and colleagues132 showed that diet therapy 
alone, resulting in a 5 kg reduction in body weight over four 
months, did not significantly alter the forearm blood flow or 
blood pressure response to either mental stress or handgrip 
exercise in obese 10-year-old children. Blood pressure 
responses were higher and forearm blood flow responses were 
lower in the obese versus lean children at baseline. However, 
in that report a combination of the dietary intervention 
plus aerobic training on three days per week did result in 
improved blood pressure and blood flow responses similar 
to those of nonobese controls.132 Further, both diet-alone and 
diet-plus-exercise groups had similar reduction in body mass, 
fasting glucose, insulin, and total cholesterol, suggesting that 
exercise was primarily responsible for promoting improved 
vascular control.
An additional component of dietary therapy that has 
received attention is antioxidant supplementation. Several 
studies in adults showed that vitamin C and E supplemen-
tation may partially prevent the acute effect of a high fat 
meal to induce vascular dysfunction, measured by arterial 
elasticity, flow mediated dilation, or response to the vaso-
dilator, L-arginine.133–135 Since obesity and vascular disease 
are frequently associated with markers of inflammation or 
oxidative damage, antioxidant supplementation trials have 
been performed, but the results have been mixed. Examples 
of favorable results in overweight adults include a recent 
study in which a daily dose of vitamins C and E plus beta-
carotene for eight weeks produced small improvements in 
levels of vascular endothelial adhesion markers.136 Another 
trial in middle-aged obese adults showed that fibrinolysis was 
improved after three months of vitamin C supplementation.137 
The limited data available on antioxidant supplementation in 
children has also favored positive results. In the Endothelial 
Assessment of Risk from Lipids in Youth (EARLY) study a 
small group of participants (aged 8–20 years) with familial 
hyperlipidemia was given 250 mg of vitamin C and 200 IU 
of vitamin E twice daily for six weeks in a double-blind, ran-
domized, placebo-controlled crossover trial.138 Compared to 
baseline, a standard diet phase, or the placebo phase, brachial 
FMD was significantly higher (∼60%) following the antioxi-
dant supplement period. The improvement in FMD occurred 
in the absence of significant changes in blood pressure, lipids, 
or C-reactive protein. Using a similar study design the same 
investigative team also reported improvement in FMD in 
response to supplementation with the omega-3 fatty acid, 
docosahexaenoic acid (1.2 g/day), taken for six weeks by 
children and adolescents with hyperlipidemia.139
In contrast to those positive data, several studies have 
reported that experimental supplementation of vitamins C 
and/or E had no beneficial effects on, for example, arte-
rial compliance, blood pressure or endothelial function in 
healthy young or older adults, adults with type 2 diabetes, or Vascular Health and Risk Management 2009:5 982
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arterial disease patients.140–142 Likewise, most larger clinical 
trials of antioxidant vitamins, particularly vitamin E, failed 
to demonstrate benefits on cardiovascular and mortality 
outcomes in adults.143,144 Of greater concern is the finding 
from a meta-analysis that daily supplementation of vitamin 
E exceeding 400 IU per day was associated with increased 
mortality.145 Negative results were also noted for trials of 
beta carotene and vitamin A.146 It should be noted that the 
increased risk for vitamin E was demonstrated in trials using 
vitamin E alone, which may limit its effectiveness and be 
responsible for the negative outcomes. Further, many trials 
were often small and performed on patients with chronic 
diseases, making the generalization to all adults and children 
uncertain. Vitamin C, alone or in combination with vitamin E 
or other antioxidants, may still have some potential for ben-
eficial application as a supplement,143 but further trials, 
especially in obese or diabetic children will be needed to 
resolve whether their use should be promoted. At present, it 
is recommended that children and adults receive adequate 
sources of antioxidant vitamins through a normal diet rich in 
fruits and vegetables. Following both the American Diabetes 
Association (ADA) and DASH diets is likely to substantially 
increase the antioxidant content, obviating the need for addi-
tional antioxidant supplements.
Although diet and exercise each may have beneficial 
effects on vascular function individually, combined exercise 
and nutritional interventions are employed increasingly 
to address the complications of obesity in children. For 
example, a group of 135 obese children (mean age 12 years) 
were enrolled in a six-month intervention program (N = 75) 
consisting of behavioral, nutritional, and supervised exercise 
components, or a standard of care control group who contin-
ued to be observed by pediatricians and provided office-based 
nutritional guidance.147 The intervention group lost an average 
of 2.6 kg while the control group continued to gain weight 
(5 kg). Those in the intervention also reduced total cholesterol 
and fasting insulin although there was not a treatment effect 
on LDL-C or HDL-C or triglycerides and effects on vascular 
function were not described. In a smaller study lasting three 
months in duration, a program of combined behavioral, nutri-
tional and aerobic exercise (walking) resulted in only a small 
reduction in BMI in obese adolescents but led to significant 
reductions in several inflammatory markers, the concentra-
tion and synthesis rate of fibrinogen, and the concentration of 
the fibrin split product, D-dimer.24,25 These findings suggest 
that thrombotic risk, which is increased in obese children, is 
reduced following a relatively short intervention period with 
modest changes in behavior.
Pharmacological treatment
Since the prevalence of obesity and type 2 diabetes in child-
hood and adolescents has risen rapidly over just the past two 
decades, there has been scant scientific evidence gathered to 
fully evaluate the efficacy of pharmacological treatments on 
vascular outcomes in such children. Treatment guidelines 
for glycemic, lipid, and blood pressure control in children 
have been proposed in recent years, and are discussed below. 
Guidelines for management of hypertension in children are 
included but are reviewed in more detail elsewhere.148
Glycemic control
The first line of pharmacologic treatment for newly diagnosed 
children with type 2 diabetes is metformin. Metformin is well 
tolerated in children149 and has a favorable effect on glucose 
control primarily by decreasing hepatic glucose production. 
Metformin treatment is also associated with less weight gain 
compared to other oral agents, lowers triglyceride levels, 
and may modify cardiovascular risk. People with obesity 
without diabetes, who have failed lifestyle management, 
increasingly are being treated with metformin, particularly 
if they have impaired glucose tolerance, polycystic ovarian 
syndrome, and/or have a family history of diabetes.150 There 
are only minor and transient side effects associated with 
metformin therapy in the majority of adolescent patients.150 
Mild abdominal discomfort and diarrhea are the most fre-
quent and usually resolve within six weeks. The risk of lactic 
acidosis in type 2 diabetic patients treated with metformin is 
approximately 0.03 per 1,000 patient years; the predisposing 
factors for acidosis in adults are renal and/or atherosclerotic 
cardiovascular disease, liver disease, or alcohol abuse.151–153 
Long-term metformin use may be associated with decreased 
intestinal absorption of vitamin B12 and folate but the magni-
tude of reductions in plasma B12 and folate are not believed 
to be significant in adults and can be reversed on discontinu-
ation.153 Comparable data in adolescents are needed.
Lipid management
Guidelines from the ADA, incorporating recommendations 
by the American Heart Association (AHA), suggest the use 
of pharmacologic agents (statins) when the LDL-C remains 
above 130 mg/dL (3.4 mmol/L) after lifestyle interven-
tion, when one or more cardiovascular disease risk factors 
(including diabetes) is present. The authors recommend the 
use of a statin in type 2 diabetic with the goal of attaining an 
LDL-C of less than 100 mg/dL (2.6 mmol/L), since safety 
and efficacy have been documented in children with familial 
hypercholesterolemia as young as eight years old.154 Statins 
may have additional benefit for the diabetic patient since they Vascular Health and Risk Management 2009:5 983
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have the effect of reducing inflammation and oxidation via 
their pleiotrophic effects.155
Other less effective agents can be used for hyperlipidemia, 
either alone or in combination with a statin. Bile acid-binding 
resins have a long track record of safety in children, but 
have not been well tolerated because of failure to dissolve 
as a powder, resulting in an unpleasant gritty and sandy 
taste. Cholesevelam, taken as a large-sized 625 mg pill, 
has successfully lowered lipids, with improved palatability, 
although cramping and bloating can be expected. These effects 
can be offset by the concomitant use of psyllium-containing 
laxatives. Niacin has not been acceptable for use in childhood 
because of the frequent occurrence of flushing and elevation 
in liver enzymes.156 Early evidence supports safety, efficacy 
and low side effect profile in children with familial hyper-
cholesterolemia for ezetimibe (Zetia), a specific cholesterol 
absorption inhibitor acting on the Nieman-Pick-Like L1 
protein located on the intestinal brush border endothelium.157 
This drug has potential for use alone and in combination with 
a statin. The dual synergistic effect on inhibiting intestinal 
cholesterol absorption and down-regulating the increased 
hepatic cholesterol synthesis may lower the dose requirement 
of concomitant statin used. However, a study on intensive 
lipid lowering with combined simvastatin and ezetimibe in 
aortic stenosis (SEAS) demonstrated limited efficacy while 
cancer occurred more frequently in the combination treatment 
group.158 Subsequently analyses from three ezetimibe trials 
failed to provide clear evidence that the drug affected cancer 
rates159 and pre-clinical testing failed to show tumor-promoting 
effects.160 Nevertheless, longer follow-up for potential cancer 
risk has been recommended.159 In adults ezetimibe has largely 
been used in combination with high statin doses in efforts to 
attain recommended lipid goals. Since lipid goal achievement 
may be attained in combination at a lower statin dose than 
that required with a statin alone, the combination may be 
especially attractive in children. Ezetimibe monotherapy has 
been shown in a small retrospective series involving children 
and adolescents157 to be safe and efficacious for lowering 
LDL-C. Consequently it has been recommended as a suit-
able choice considering its good palatability compared to 
bile acid-binding resins, low side-effect profile and less than 
20% gastrointestinal absorption.
Unfortunately, additional treatment targets including 
triglyceride and HDL-C values have rarely been considered 
in childhood, even though they are recognized components 
of the metabolic syndrome, and incremental benefit on 
cardiovascular risk may be attained by aggressive treat-
ment of these components. Recent treatment consensus 
recommendations for triglycerides have been published.161 
Treatment of triglyceride concentrations between 150 and 
400 mg/dL consists of limiting of dietary intake of simple 
sugars and saturated and trans fats, and weight loss man-
agement incorporating physical activity. In obese children 
aged over 10 years, use of a fibrate should be considered 
when the triglyceride is above 700 mg/dL to offset the risk 
of pancreatitis. It should be noted however that combining a 
fibrate with a statin is contraindicated in childhood because 
of the increased potential for myopathy and rhabdomyolysis. 
It is likely that the emergence of newer technologies allow-
ing measurements of vascular pathology (IMT, PCA, PWV , 
etc.) may serve as a stimulus for a reappraisal of treatment 
guidelines related to the use of pharmacologic agents in 
treatment of various forms of hyperlipidemia.
An HDL-C target for children with type 2 diabetes has 
not been established other than to attempt normalization by 
increasing physical activity. A meta-analysis of randomized 
controlled trials showed that aerobic exercise decreases 
triglycerides in obese and overweight children and adolescents 
with a trend for increased HDL-C.162 Nevertheless, levels 
of HDL-C often remain below the normal range in the face 
of insulin resistance with or without diabetes. Treatment of 
elevated cholesterol or triglyceride with a statin or a fibrate 
may have a moderate effect on rasing HDL-C. Low HDL-C 
concentration and resistance to change in response to treat-
ment in insulin resistant patients may in part be mediated by 
a pleiotropic effect of specific genes on elevating triglyceride 
and lowering HDL-C.163,164
At the onset of type 2 diabetes it is common to find 
hypertriglyceridemia, low HDL-C and moderately high 
LDL-C accompanying insulin resistance and relative beta 
cell failure. Consequently high rates of dyslipidemia in 
type 2 diabetes approaching and exceeding 50%, have been 
recorded, depending on the definition.165,166 Dyslipidemia 
is often reversible with adequate diabetes treatment, but in 
many cases the primary LDL-C target is not achieved and 
ongoing treatment with lipid-lowering medications is indi-
cated. Prevalence rates for abnormal LDL-C greater than 
160, 130, and 100 mg/dL in youth with type 2 diabetes have 
been reported as 9%, 24%, and 57%,167 much higher than 
those with type 1 diabetes (3%, 14%, and 48% for the same 
LDL-C cut points). However, data suggest that physicians 
tend to use lipid-lowering therapy sparingly, possibly because 
of a lack of outcome data for this age group.167 Compliance 
with ADA and AHA guidelines requires a more aggressive 
approach than is currently practiced to achieve optimal 
glycemic control and attain the recommended primary Vascular Health and Risk Management 2009:5 984
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target (LDL-C  100 mg/dL) and secondary targets 
(HDL-C  35 mg/dL, triglyceride  150 mg/dL).166 This 
needs to begin with comprehensive lifestyle education with 
family participation and should include discussion of weight 
control, tobacco cessation and physical activity. Since the 
decision to treat with a lipid-lowering agent is based on 
lipid levels and associated risk factors, regular and accu-
rate monitoring at least every three months is required for 
assessing the status of the conventional metabolic syndrome 
criteria (height and weight measurements to determine BMI, 
lipid profile, including triglyceride, cholesterol, HDL-C, 
calculated LDL-C and non-HDL-C and blood pressure.
Additional nontraditional markers of cardiovascular dis-
ease in children are available and might support a decision to 
treat, particularly when there is a family history of cardiovas-
cular events.168 Such novel markers of risk are generally only 
recommended as part of approved ongoing investigations 
and should not be relied on as predictors without conclusive 
data in this age group. Nevertheless, popular lipid/lipoprotein 
measures known to predict risk in adults such as apoB, LDL 
particle number and non-HDL (obtained by subtracting the 
HDL-C from the total cholesterol) and Lp(a) may be help-
ful to guide treatment decisions, although normal ranges for 
adolescents have not been established. Non-HDL-C levels are 
approximately 30 mg/dL above those for LDL-C. C-reactive 
protein assay is available as an inflammatory marker and a 
predictor of cardiovascular disease in the patient without 
other causes of transient inflammation. Elevated C-reactive 
protein has been associated with obesity in adolescents,169 
but is not specific to obesity and may be spuriously increased 
by acute and chronic inflammatory conditions. Elevated liver 
enzymes such as alanine aminotransferase and aspartic acid 
aminotransferase, have recently been observed in association 
with the metabolic syndrome in obese children, indicating the 
presence of hepatic steatosis.170 IMT tends to be increased 
in adolescent patients with steatosis suggesting additional 
cardiovascular risk.171 Therefore moderate transaminase 
elevation, a common finding at the onset of type 2 diabetes, 
warrants detection, evaluation and intensification of the 
treatment plan.172
The decision to treat elevated LDL-C with a statin must 
take into consideration its possible long-term harmful effects. 
Pregnancy counseling and avoidance of teratogenic effects 
need to be considered when prescribing for the teenage 
female. Cross-reactivity with other agents with common 
disposal pathways can result in increased levels of the statin 
and risk for myositis and potential rhabdomyolysis, although 
the risk is lower at young ages and when the patient is free 
of renal and hepatic disease. Consequently monitoring for 
increases in muscle creatinine kinase and liver enzymes is 
recommended at baseline and if symptoms occur. There is 
ample short-term trial evidence for efficacy and safety of 
statins in adolescence, although trials for statins and other 
lipid-lowering agents are ongoing.155,173
Hypertension
It has been estimated that hypertension is eight times more 
frequent in adolescents with type 2 diabetes than with type 1 
diabetes165 and the prevalence at presentation varies between 
10% to 32%.174,175 The incidence of hypertension (systolic 
or diastolic blood pressure 95th percentile) in the recent 
TODAY trial was 17%, with 29% of type 2 diabetic subjects 
having a blood pressure greater than the 90th percentile, 
according to age, sex, and height.5 After controlling diabetes, 
the recommended approach to treatment of hypertension 
is to begin with lifestyle. The 4th taskforce of the High 
Blood Pressure Education Program recommends the dietary 
principals of the Dietary Approaches to Stop Hypertension 
(DASH) diet consisting of fruits, vegetables, low fat dairy, 
whole grains, reduced saturated fat, refined sugar, and low 
salt.148 Since there is overlap with components of the ADA 
recommendations for diabetes, the recommended dietary 
plans are compatible, with the emphasis on low salt intake 
if hypertension is present.
The 4th taskforce guidelines also recommend treatment 
to a goal of less than the 95th percentile for primary hyper-
tension and less than the 90th percentile for patients with 
diabetes or when there is evidence of target organ damage. 
ACE inhibitors are considered as first line pharmacological 
treatment and there are efficacy and safety data for the use 
of enalapril, fosinopril, and lisinopril in childhood.176 Prior 
to treatment a baseline measurement of renin activity is 
recommended as a guide to whether there is salt-sensitivity 
or a renal-vascular component and can serve to aid in selec-
tion of treatment. If the renin is low, a diuretic is indicated, 
as in adults.177 The treatment sequence should begin with 
the recommended initial dose of the desired medication 
and an increase in the dose until the blood pressure target 
or maximum dose is reached. If blood pressure control is 
not achieved, a second medication with a complementary 
mechanism of action should be added. If blood pressure 
control is still not achieved a third antihypertensive drug of 
a different class may be added, but at this point it is advisable 
to consult a physician specializing in treatment of children 
and adolescents with hypertension. Cases with an elevated 
plasma renin activity need urgent consultation.Vascular Health and Risk Management 2009:5 985
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Future directions and conclusions
Extensive evidence suggests that the foundations for vascular 
disease in adults are laid in childhood and accelerated by the 
co-existence of disease, including but not limited to diabetes, 
hypertension, obesity, and hyperlipidemia. As summarized in 
Table 1, current understanding of the effects of obesity and 
type 2 diabetes on vascular health in youth is incomplete. 
However, the recent development of noninvasive methods 
for assessing vascular health has made it possible to make 
precise and reproducible measures of vascular function and 
anatomic pathology early in the course of development of 
vascular disease, and is expected to result in the proliferation 
of data related to its origins. Current evidence suggests that 
many of the risk factors for vascular disease can be reduced by 
early intervention, including both lifestyle (dietary, exercise, 
and simple changes in physical activity) and pharmacologic 
(glycemic, blood pressure, and lipid control) interventions. 
The inevitable progression of vascular disease with aging 
suggests that the management of risk factors for vascular 
disease should begin with prevention, through early life-
style interventions, well before the development of obesity 
and diabetes. Unfortunately, lifestyle interventions can be 
costly, are poorly reimbursed, and often ineffective due to 
poor compliance, resulting in the need for pharmacologic 
intervention. When attempts at lifestyle modification fail, 
the use of pharmacologic interventions (to effect glucose, 
blood pressure, and lipid control), even in childhood, are 
recommended, with careful monitoring and a willingness to 
alter the prescribed therapy as needed in order to achieve the 
target values outlined by expert panels.
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